With this Loyola Medicine video, hear a candid report from Dr. Daniel Dilling, medical director of Loyola’s lung transplant program, and patient Diane Williams about Diane’s long-awaited lung transplant. Learn more about some of the myths about lung transplantations. Diane is a retired special education teacher who had always enjoyed a high-energy…
Physical inactivity and low blood-oxygen levels during periods of exercise predict poor survival in patients with idiopathic pulmonary fibrosis (IPF), according to researchers at the Rabin Medical Center in Israel. The study, “Physical Activity and Exertional Desaturation Are Associated with Mortality in Idiopathic Pulmonary Fibrosis,” published in the Journal of…
Researchers are one step closer to understanding the molecular mechanism of action of pirfenidone, the anti fibrotic drug for the treatment of pulmonary fibrosis. This may help improve the safety and efficacy of the drug, which is often used in very high doses to achieve therapeutic effectiveness, causing a range of adverse side effects.
The Duke Clinical Research Institute (DCRI) and Boehringer Ingelheim Pharmaceuticals are expanding the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, an academic-industry alliance between the two to better understand outcomes and disease progression in people with idiopathic pulmonary fibrosis (IPF), a rare lung disease. The expansion will…
Coughing and shortness of breath are main symptoms and complications of a condition called idiopathic pulmonary fibrosis (IPF). IPF is a subcategory of pulmonary fibrosis, a lung disease that causes scarring of the lungs which makes breathing difficult. IPF has no known cause and no current available cure, although some treatment options exist to ease…
Coughing and shortness of breath are the main symptoms and complications of a condition called idiopathic pulmonary fibrosis (IPF). IPF is a subcategory of pulmonary fibrosis, a chronic and typically progressive scarring lung disease. Some patients live many years with this disease, while some may have a shorter life with it.
The National Heart, Lung and Blood Institute has awarded Vanderbilt University Medical Center (VUMC) an $11 million project renewal grant to investigate the genetics and biological processes that contribute to idiopathic pulmonary fibrosis (IPF). IPF has been a focus of study for Dr. Timothy Blackwell, a professor at the Ralph…
DS Biopharma, a privately held Dublin-based company with a proprietary bioactive lipid technology platform, has launched Afimmune, a spin-off focused on approaches to treating fibrosis and fibrotic conditions. These includenon-alcoholic steatohepatitis (NASH) and atopic dermatitis, as well as other inflammatory and pulmonary disorders such as chronic obstructive pulmonary disease (COPD), and…
Metformin, a first line medication for the treatment of type 2 diabetes, reduces inflammation and pulmonary fibrosis in mice, suggests a study published in the Journal of Korean Medical Science.
Researchers at the Chinese Nanjing University School of Medicine in China discovered yet another microRNA that contributes to the development of lung fibrosis. MicroRNA are small molecules known to control gene activity. The study, “MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1,” published in the…
Get regular updates to your inbox.
